Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Desirability and expectations of the UK MS Register: Views of people with MS.
[Retrovirus superantigen hypothesis of multiple sclerosis.]
Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Neuromyelitis optica spectrum disorders without and with autoimmune diseases.
[Use of vitamins for correction of the functional state of cytochrome P450 systems at experimental allergic encephalomyelitis].
Epidemiological characteristics of acute disseminated encephalomyelitis in Nanchang, China: a retrospective study.
MRI outcomes in the diagnosis and disease course of multiple sclerosis.
Obstructive Sleep Apnea is an Under-Recognized and Consequential Morbidity in Multiple Sclerosis.
Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis.
Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.
Treatment of sleep disorders may improve fatigue in multiple sclerosis.
Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs.
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
Production, crystallization and neutron diffraction of fully deuterated human myelin peripheral membrane protein P2.
Modulation of multiple sclerosis by sunlight exposure: Role of cis-urocanic acid.
Electrophysiological Evaluation of Chronic Inflammatory Demyelinating Polyneuropathy and Charcot-Marie-Tooth Type 1: Dispersion and Correlation Analysis.
HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.
Care patterns in multiple sclerosis: principal care, comprehensive team care, consortium care.
The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom.
Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.
A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada.
Neuroplasticity in Early Onset Multiple Sclerosis.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).

Pages